Anixa Biosciences

ANIX

Market cap $110M

Overview Fund Activity

3.35 USD

-0.25

6.94%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

3.50

+0.15

4.48%

1 day

-6.94%

5 days

10.2%

1 month

12.42%

3 months

-8.97%

6 months

10.56%

Year to date

41.35%

1 year

-2.62%

5 years

41.35%

10 years

-43.22%

About: Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Employees: 5

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 3

56% more call options, than puts

Call options by funds: $67K | Put options by funds: $43K

14% more funds holding

Funds holding: 58 [Q1] → 66 (+8) [Q2]

10% more capital invested

Capital invested by funds: $16M [Q1] → $17.6M (+$1.62M) [Q2]

0.8% less ownership

Funds ownership: 17.41% [Q1] → 16.61% (-0.8%) [Q2]

8% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 12

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

109% upside

Avg. target

$8.5

154% upside

High target

$10

199% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Yi Chen	$7	Buy Reiterated	11 Sep 2025
D. Boral Capital Jason Kolbert	$10	Buy Maintained	9 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about ANIX published over the past 30 days

3 Under-the-Radar Biotechs Under $5 That Could Soar 200%

Investing in biotechnology stocks is typically reserved for speculative investors. For starters, many of these companies are clinical or pre-clinical stage companies.

3 Under-the-Radar Biotechs Under $5 That Could Soar 200%

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Continue to observe a positive safety profile—no dose limiting toxicities, cytokine release syndrome or immune effector cell-associated neurotoxicity SAN JOSE, Calif. , Sept. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced it has completed dosing of the fourth cohort in its ongoing Phase 1 clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian cancer.

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

SAN JOSE, Calif. , Sept. 2, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the time of management's presentation at the H.C.

Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SAN JOSE, Calif. , Aug. 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the H.C.

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Notice of Allowance marks first Chinese patent to be issued on Anixa Breast Cancer Vaccine Expands global intellectual property coverage in markets with high breast cancer incidence New patent will provide IP protection of Breast Cancer Vaccine in China into at least the 2040s SAN JOSE, Calif. , Aug. 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Chinese National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a new patent related to its breast cancer vaccine technology.

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Fourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to Date SAN JOSE, Calif. , Aug. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient in the fourth dose cohort has been treated in the ongoing Phase 1 clinical trial evaluating the Company's novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer.

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif. , Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 12,384,826 covering its chimeric antigen receptor-T cell (CAR-T) technology.

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Dr. Wenham is Principal investigator on Anixa's CAR-T therapy for Ovarian Cancer SAN JOSE, Calif. , Aug. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center and principal investigator for the Company's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will be presenting at the 13th Annual Ovarcoming Cancer Conference, being held September 18 – 19, 2025, virtually and in-person at the Briar Club in Houston, Texas.

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

Progress Follows Positive Immune Response Observed in Phase 1 Study SAN JOSE, Calif. , Aug. 4, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in collaboration with Cleveland Clinic, it has initiated the transfer of the Investigational New Drug (IND) application that supported the Phase 1 clinical trial of its breast cancer vaccine.

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

Patent Strengthens International Protection for First-of-Its-Kind Immunopreventive Platform Expands Global IP Coverage in Markets with High Incidence of Breast Cancer SAN JOSE, Calif. , July 30, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a new patent related to its breast cancer vaccine technology.

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

See News Rankings

Charts implemented using Lightweight Charts™